Alan Robert Ross
Research analyst, value, Growth, newsletter provider

Provectus Pharmaceuticals: Small Cap, Huge Upside

Provectus Pharmaceuticals: Small Cap, Huge Upside

EXECUTIVE SUMMARY

Provectus (NYSEMKT:PVCT) is a small biotech company whose lead candidate, PV-10 has been granted FDA Orphan Drug Status for the treatment of highly lethal metastatic melanoma and metastatic liver cancer. It has a successful and expanding Compassionate Use program in operation and successfully completed trials on metastatic cancer of the breast, liver and melanoma, with positive results. The data suggest that intralesional injection kills cancer cells and not normal cells, with no debilitating side-effects. As if that is not enough, a single injection acts as immunotherapy, prompting the patient's immune system to attack tumors remote from the one injected. Given that PV-10 has an outstanding safety profile, no debilitating treatment...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
PRO Top long ideas returned 21.7% in 2016**
"As a PRO member, we get uniquely valuable perspective that go beyond our quantiative analysis... We rely on PRO to get beyond the numbers quickly and add much needed perspective. It keeps me ahead of the next big thing. - Mark Choate, Malaga Cove Capital"
Mark Choate, Malaga Cove Capital
"Contributors (writers and commentators), often have a long history in the secuirities they opine on and some are clearly well positioned industry participants with detailed industry views that can help provide color on where the skeletons are buried in a particular secuirity and/or industry."
Jim Roumell, Roumell Asset Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details